Evaluation of MRI Measures of Lung Water With Posture Changes in Healthy Volunteers and in Patients With Cardiac Failure

NCT ID: NCT01277679

Last Updated: 2014-06-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-01-31

Study Completion Date

2011-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to establish a model for the evaluation of drug targets using postural measures to induce changes in lung water concentration as assessed by MRI. A reduction in the magnitude and rate of water transudation with postural changes in patients with congestive heart failure (CHF) could provide a model for the evaluation of various classes of molecules for target validation and for dose selection.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure, Congestive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy Volunteer

Healthy Volunteer cohort

Group Type OTHER

MRI

Intervention Type PROCEDURE

MRI of lungs to measure lung water content before and after passive leg raising (PLR)

Heart Failure

Heart Failure cohort

Group Type OTHER

MRI

Intervention Type PROCEDURE

MRI of lungs to measure lung water content before and after passive leg raising (PLR)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MRI

MRI of lungs to measure lung water content before and after passive leg raising (PLR)

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Heart Failure Patients:
* Established diagnosis of mild to moderate heart failure of any aetiology with symptoms defined as corresponding to the New York Heart Association (NYHA) class I, II or III
* Able in the opinion of the patient and investigator to be supine for 1 hour and to experience passive leg raising (PLR) whilst in the MRI scanner
* Male or female over 18 years of age at the time of signing the informed consent
* Negative urine or serum pregnancy test
* Capable of giving written informed consent
* Registered with a UK general practitioner.
* Participants must read (in English) at a level sufficient to adequately complete study related questionnaires
* Able to understand and comply with protocol requirements, instructions and protocol-stated restrictions
* Healthy Volunteers:
* Healthy as determined by a responsible physician
* Male or female over 18 years of age at the time of signing the informed consent
* Capable of giving written informed consent
* Negative urine or serum pregnancy test
* Registered with a UK general practitioner
* Participants must read (in English) at a level sufficient to adequately complete study related questionnaires
* Able to understand and comply with protocol requirements, instructions and protocol-stated restrictions

Exclusion Criteria

* Heart Failure Patients
* History of primary pulmonary disease requiring current medication or other therapy.
* Orthopnoea of sufficient severity to preclude supine scanning.
* Hip or leg pathology of sufficient severity to prevent extension of both legs to 45 degrees.
* Unstable heart failure, defined as change in NYHA status, change in heart failure therapy regimen or hospitalization for acute decompensation of heart failure within preceding 6 weeks.
* Unstable angina within the past 3 months
* Current smoker, defined as having smoked in the preceding 1 year
* Uncontrolled hypertension (resting systolic BP \> 160 mmHg or resting diastolic BP \> 100mmHg)
* Resting hypoxia (SaO2 \<93%).
* Contraindication to MRI scanning
* Pregnant females
* Positive drugs of abuse or alcohol screen.
* Unwillingness or inability to follow the procedures outlined in the protocol.
* Healthy Volunteers
* History of primary pulmonary disease requiring current medication or other therapy
* Current smoker, defined as having smoked in the preceding 1 year
* Hip or leg pathology of sufficient severity to prevent extension of both legs to 45 degrees
* Contraindication to MRI scanning
* Pregnant females
* Positive drugs of abuse or alcohol screen
* Unwillingness or inability to follow the procedures outlined in the protocol
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GlaxoSmithKline

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GSK Investigational Site

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

114747

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.